Share Price and Basic Stock Data
Last Updated: January 22, 2026, 8:25 am
| PEG Ratio | 5.30 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Wockhardt Ltd, a prominent player in the Indian pharmaceuticals sector, reported a market capitalization of ₹21,891 Cr with a current share price of ₹1,349. The company has experienced fluctuating sales, recording ₹679 Cr in September 2022, which rose to ₹753 Cr by September 2023, showcasing a year-on-year growth trajectory. However, quarterly revenue demonstrated variability, peaking at ₹809 Cr in September 2024 before a slight decline to ₹721 Cr in December 2024. Over the past fiscal years, Wockhardt’s sales stood at ₹4,830 Cr in March 2014, dwindling to ₹2,651 Cr by March 2023, indicating challenges in sustaining top-line growth. Notably, the trailing twelve months (TTM) revenue is reported at ₹2,984 Cr. While operational performance showed some recovery, with an operating profit margin (OPM) reaching 23% in September 2025, the overall historical sales trend remains concerning, necessitating strategic initiatives to bolster revenue generation.
Profitability and Efficiency Metrics
Wockhardt’s profitability metrics reflect a challenging financial landscape, with a reported net profit of -₹51 Cr. The company’s return on equity (ROE) stood at a mere 1.22%, and return on capital employed (ROCE) was recorded at 3.75%, both significantly below the industry averages, indicating inefficiencies in capital utilization. The operating profit margin (OPM) fluctuated, recording 2% in June 2023 and rising to 23% by September 2025, suggesting potential operational improvements. Despite this, the company faced a net loss of ₹621 Cr in March 2023, which slightly improved to a loss of ₹57 Cr by March 2025. The interest coverage ratio (ICR) of 1.79x indicates a precarious position concerning debt servicing, especially given the high interest burden reported at ₹302 Cr in March 2023. This combination of low profitability and high leverage poses risks, necessitating a focus on enhancing operational efficiency and managing costs.
Balance Sheet Strength and Financial Ratios
Wockhardt’s balance sheet reflects a mix of strengths and vulnerabilities, with total borrowings amounting to ₹2,456 Cr against reserves of ₹4,486 Cr as of September 2025. The company has maintained a current ratio of 1.26, indicating adequate short-term liquidity to cover liabilities. However, the debt-to-equity ratio of 0.42 suggests a moderate level of financial leverage. The book value per share, reported at ₹268.70, offers a cushion against market volatility, yet the price-to-book value ratio of 5.30x indicates a premium valuation compared to typical sector norms. The cash conversion cycle (CCC) of 123 days reflects operational inefficiencies relative to industry standards, which generally hover around 60-90 days. Furthermore, the asset turnover ratio of 0.38% highlights challenges in generating revenue from assets, suggesting that Wockhardt needs to optimize its asset utilization to enhance financial performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Wockhardt Ltd showcases a diversified ownership structure, with promoters holding 49.09% of the equity, while institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), collectively hold 18.10%. This stability among promoters, down from 60.36% in December 2022, reflects a gradual dilution of control, which may signal strategic shifts. The public holds 32.79% of shares, indicating a healthy retail interest. Notably, the number of shareholders has decreased to 1,37,946 as of September 2025, from 1,84,908 in December 2022, which may raise concerns regarding investor confidence. The increasing institutional shareholding, particularly DIIs rising to 11.00%, can be interpreted as a positive sentiment toward the company’s long-term potential, despite the short-term financial challenges faced.
Outlook, Risks, and Final Insight
Wockhardt’s outlook remains clouded by significant risks, including its ongoing profitability struggles and high debt levels. The company must focus on operational efficiencies to improve margins and restore investor confidence. Strengths include its established market presence and diversified product portfolio, which could be leveraged to capture growth opportunities. However, risks such as fluctuating sales, operational inefficiencies, and a high interest burden can impede recovery efforts. The company’s ability to navigate regulatory challenges and market dynamics will be crucial in determining its future trajectory. To enhance shareholder value, Wockhardt should prioritize cost management and explore strategic partnerships or acquisitions that align with its core competencies. A successful turnaround could position the company favorably in a competitive pharmaceutical landscape, potentially attracting new investments and stabilizing its market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 203/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,425 Cr. | 315 | 479/192 | 70.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 59.6 Cr. | 40.7 | 41.6/17.0 | 142 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,405.19 Cr | 1,082.65 | 47.84 | 202.18 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 679 | 699 | 678 | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 |
| Expenses | 636 | 654 | 675 | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 |
| Operating Profit | 43 | 45 | 3 | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 |
| OPM % | 6% | 6% | 0% | 2% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% |
| Other Income | -138 | -1 | -64 | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 |
| Interest | 70 | 83 | 76 | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 |
| Depreciation | 65 | 66 | 56 | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 |
| Profit before tax | -230 | -105 | -193 | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 |
| Tax % | -10% | -3% | 23% | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% |
| Net Profit | -207 | -102 | -237 | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 |
| EPS in Rs | -13.12 | -6.66 | -14.44 | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.80 |
Last Updated: December 28, 2025, 12:33 pm
Below is a detailed analysis of the quarterly data for Wockhardt Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 782.00 Cr.. The value appears strong and on an upward trend. It has increased from 738.00 Cr. (Jun 2025) to 782.00 Cr., marking an increase of 44.00 Cr..
- For Expenses, as of Sep 2025, the value is 604.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 666.00 Cr. (Jun 2025) to 604.00 Cr., marking a decrease of 62.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 178.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Jun 2025) to 178.00 Cr., marking an increase of 106.00 Cr..
- For OPM %, as of Sep 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 10.00% (Jun 2025) to 23.00%, marking an increase of 13.00%.
- For Other Income, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from -77.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 98.00 Cr..
- For Interest, as of Sep 2025, the value is 55.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 48.00 Cr. (Jun 2025) to 55.00 Cr., marking an increase of 7.00 Cr..
- For Depreciation, as of Sep 2025, the value is 53.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 56.00 Cr. (Jun 2025) to 53.00 Cr., marking a decrease of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from -109.00 Cr. (Jun 2025) to 91.00 Cr., marking an increase of 200.00 Cr..
- For Tax %, as of Sep 2025, the value is 10.00%. The value appears to be increasing, which may not be favorable. It has increased from -1.00% (Jun 2025) to 10.00%, marking an increase of 11.00%.
- For Net Profit, as of Sep 2025, the value is 82.00 Cr.. The value appears strong and on an upward trend. It has increased from -108.00 Cr. (Jun 2025) to 82.00 Cr., marking an increase of 190.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.80. The value appears strong and on an upward trend. It has increased from -5.54 (Jun 2025) to 4.80, marking an increase of 10.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:23 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,830 | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 2,984 |
| Expenses | 3,805 | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,550 | 2,707 | 2,619 | 2,542 |
| Operating Profit | 1,026 | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 101 | 91 | 393 | 442 |
| OPM % | 21% | 16% | 11% | 0% | 0% | -1% | 4% | -2% | 9% | 4% | 3% | 13% | 15% |
| Other Income | 88 | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -172 | 17 | 62 | -33 |
| Interest | 83 | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 211 |
| Depreciation | 140 | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 217 |
| Profit before tax | 891 | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -16 | -19 |
| Tax % | 5% | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | -0% | 12% | 256% | |
| Net Profit | 843 | 413 | 252 | -226 | -667 | -217 | -43 | 689 | -279 | -621 | -472 | -57 | -51 |
| EPS in Rs | 58.91 | 28.30 | 17.45 | -13.62 | -42.30 | -13.52 | -4.81 | 47.64 | -16.94 | -38.80 | -30.18 | -2.89 | -1.42 |
| Dividend Payout % | 13% | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -51.01% | -38.98% | -189.68% | -195.13% | 67.47% | 80.18% | 1702.33% | -140.49% | -122.58% | 23.99% | 87.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | 12.03% | -150.70% | -5.45% | 262.60% | 12.72% | 1622.14% | -1842.82% | 17.91% | 146.57% | 63.93% |
Wockhardt Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 1% |
| 3 Years: | -2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 15% |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 40% |
| 3 Years: | 79% |
| 1 Year: | 36% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: December 10, 2025, 3:40 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 | 81 |
| Reserves | 3,228 | 3,362 | 3,720 | 3,281 | 2,797 | 2,619 | 2,616 | 3,321 | 3,777 | 3,282 | 3,282 | 4,272 | 4,486 |
| Borrowings | 2,205 | 2,309 | 2,677 | 4,160 | 3,748 | 3,375 | 3,582 | 2,673 | 2,198 | 2,184 | 2,356 | 2,021 | 2,456 |
| Other Liabilities | 1,134 | 1,213 | 1,622 | 1,486 | 1,528 | 1,764 | 1,894 | 1,695 | 2,168 | 2,113 | 1,899 | 1,726 | 1,510 |
| Total Liabilities | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,744 | 8,215 | 7,651 | 7,614 | 8,100 | 8,533 |
| Fixed Assets | 2,295 | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 | 4,396 |
| CWIP | 708 | 1,007 | 1,036 | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 2,033 | 583 |
| Investments | 577 | 341 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 | 696 |
| Other Assets | 3,043 | 3,468 | 4,228 | 4,403 | 3,593 | 3,309 | 3,060 | 3,022 | 3,411 | 3,070 | 3,011 | 2,909 | 2,858 |
| Total Assets | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,744 | 8,215 | 7,651 | 7,614 | 8,100 | 8,533 |
Below is a detailed analysis of the balance sheet data for Wockhardt Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 81.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 81.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,486.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,272.00 Cr. (Mar 2025) to 4,486.00 Cr., marking an increase of 214.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,456.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,021.00 Cr. (Mar 2025) to 2,456.00 Cr., marking an increase of 435.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,510.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,726.00 Cr. (Mar 2025) to 1,510.00 Cr., marking a decrease of 216.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,533.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,100.00 Cr. (Mar 2025) to 8,533.00 Cr., marking an increase of 433.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,396.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,736.00 Cr. (Mar 2025) to 4,396.00 Cr., marking an increase of 1,660.00 Cr..
- For CWIP, as of Sep 2025, the value is 583.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,033.00 Cr. (Mar 2025) to 583.00 Cr., marking a decrease of 1,450.00 Cr..
- For Investments, as of Sep 2025, the value is 696.00 Cr.. The value appears strong and on an upward trend. It has increased from 422.00 Cr. (Mar 2025) to 696.00 Cr., marking an increase of 274.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,858.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,909.00 Cr. (Mar 2025) to 2,858.00 Cr., marking a decrease of 51.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,533.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,100.00 Cr. (Mar 2025) to 8,533.00 Cr., marking an increase of 433.00 Cr..
Notably, the Reserves (4,486.00 Cr.) exceed the Borrowings (2,456.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | 707.00 | 492.00 | 9.00 | -1.00 | -41.00 | 116.00 | -65.00 | 296.00 | 99.00 | 89.00 | 391.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 | 81 | 80 |
| Inventory Days | 201 | 250 | 249 | 243 | 174 | 183 | 209 | 256 | 222 | 216 | 201 | 234 |
| Days Payable | 113 | 136 | 144 | 117 | 122 | 187 | 272 | 223 | 265 | 285 | 240 | 191 |
| Cash Conversion Cycle | 124 | 175 | 196 | 220 | 141 | 126 | 97 | 157 | 60 | 41 | 41 | 123 |
| Working Capital Days | -7 | 14 | 52 | 36 | -56 | -51 | -171 | -133 | -116 | -186 | -163 | -23 |
| ROCE % | 18% | 10% | 7% | -1% | -1% | -1% | 0% | 12% | 1% | -0% | -1% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Tata Small Cap Fund | 1,929,375 | 2.09 | 238.28 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 1,325,150 | 1.01 | 163.66 | N/A | N/A | N/A |
| Tata Large & Mid Cap Fund | 978,826 | 1.38 | 120.89 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 837,752 | 0.69 | 103.46 | 830,222 | 2025-12-15 06:41:57 | 0.91% |
| Bandhan Small Cap Fund | 581,354 | 0.4 | 71.8 | 572,354 | 2025-12-15 06:41:57 | 1.57% |
| Invesco India Smallcap Fund | 575,064 | 0.79 | 71.02 | N/A | N/A | N/A |
| Invesco India Contra Fund | 466,063 | 0.28 | 57.56 | N/A | N/A | N/A |
| HDFC Multi Cap Fund | 451,605 | 0.28 | 55.77 | 588,567 | 2025-12-15 06:41:57 | -23.27% |
| Bank of India Small Cap Fund | 440,000 | 2.74 | 54.34 | N/A | N/A | N/A |
| ICICI Prudential Equity & Debt Fund | 392,954 | 0.1 | 48.53 | 359,543 | 2025-12-15 06:41:57 | 9.29% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | -3.02 | -32.05 | -38.79 | -20.24 | 61.95 |
| Diluted EPS (Rs.) | -3.02 | -32.05 | -38.79 | -20.24 | 61.68 |
| Cash EPS (Rs.) | 9.88 | -16.17 | -25.69 | -2.22 | 84.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 268.70 | 237.79 | 254.31 | 291.81 | 339.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 268.70 | 237.79 | 254.31 | 291.81 | 339.43 |
| Revenue From Operations / Share (Rs.) | 185.93 | 181.69 | 184.10 | 224.31 | 244.48 |
| PBDIT / Share (Rs.) | 28.09 | 7.92 | 15.49 | 22.08 | 6.25 |
| PBIT / Share (Rs.) | 14.69 | -6.56 | -1.94 | 4.93 | -15.96 |
| PBT / Share (Rs.) | -0.98 | -27.27 | -43.33 | -28.54 | 81.42 |
| Net Profit / Share (Rs.) | -3.52 | -30.65 | -43.13 | -19.38 | 62.16 |
| NP After MI And SOA / Share (Rs.) | -2.90 | -30.06 | -38.82 | -16.94 | 61.93 |
| PBDIT Margin (%) | 15.10 | 4.36 | 8.41 | 9.84 | 2.55 |
| PBIT Margin (%) | 7.90 | -3.60 | -1.05 | 2.19 | -6.52 |
| PBT Margin (%) | -0.53 | -15.01 | -23.53 | -12.72 | 33.30 |
| Net Profit Margin (%) | -1.89 | -16.86 | -23.42 | -8.63 | 25.42 |
| NP After MI And SOA Margin (%) | -1.56 | -16.54 | -21.08 | -7.55 | 25.33 |
| Return on Networth / Equity (%) | -1.07 | -13.78 | -16.66 | -6.33 | 20.31 |
| Return on Capital Employeed (%) | 3.90 | -2.07 | -0.65 | 1.40 | -3.79 |
| Return On Assets (%) | -0.57 | -6.05 | -7.27 | -2.96 | 8.82 |
| Long Term Debt / Equity (X) | 0.27 | 0.26 | 0.06 | 0.09 | 0.14 |
| Total Debt / Equity (X) | 0.42 | 0.62 | 0.56 | 0.48 | 0.46 |
| Asset Turnover Ratio (%) | 0.38 | 0.36 | 0.33 | 0.20 | 0.15 |
| Current Ratio (X) | 1.26 | 0.78 | 0.64 | 0.80 | 0.77 |
| Quick Ratio (X) | 0.90 | 0.55 | 0.45 | 0.56 | 0.52 |
| Inventory Turnover Ratio (X) | 4.41 | 0.95 | 0.72 | 0.47 | 0.48 |
| Interest Coverage Ratio (X) | 1.79 | 0.40 | 0.73 | 1.06 | 0.27 |
| Interest Coverage Ratio (Post Tax) (X) | 0.77 | -0.50 | -0.08 | 0.67 | 0.38 |
| Enterprise Value (Cr.) | 25036.75 | 10872.67 | 4287.88 | 5607.72 | 6250.83 |
| EV / Net Operating Revenue (X) | 8.31 | 3.89 | 1.62 | 1.74 | 2.31 |
| EV / EBITDA (X) | 55.03 | 89.12 | 19.23 | 17.63 | 90.28 |
| MarketCap / Net Operating Revenue (X) | 7.66 | 3.21 | 0.83 | 1.18 | 1.69 |
| Price / BV (X) | 5.30 | 2.68 | 0.66 | 0.98 | 1.36 |
| Price / Net Operating Revenue (X) | 7.66 | 3.21 | 0.83 | 1.18 | 1.69 |
| EarningsYield | 0.00 | -0.05 | -0.25 | -0.06 | 0.14 |
After reviewing the key financial ratios for Wockhardt Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has increased from -16.17 (Mar 24) to 9.88, marking an increase of 26.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 185.93. It has increased from 181.69 (Mar 24) to 185.93, marking an increase of 4.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.09. This value is within the healthy range. It has increased from 7.92 (Mar 24) to 28.09, marking an increase of 20.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 14.69. This value is within the healthy range. It has increased from -6.56 (Mar 24) to 14.69, marking an increase of 21.25.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 0. It has increased from -27.27 (Mar 24) to -0.98, marking an increase of 26.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.52. This value is below the healthy minimum of 2. It has increased from -30.65 (Mar 24) to -3.52, marking an increase of 27.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.90. This value is below the healthy minimum of 2. It has increased from -30.06 (Mar 24) to -2.90, marking an increase of 27.16.
- For PBDIT Margin (%), as of Mar 25, the value is 15.10. This value is within the healthy range. It has increased from 4.36 (Mar 24) to 15.10, marking an increase of 10.74.
- For PBIT Margin (%), as of Mar 25, the value is 7.90. This value is below the healthy minimum of 10. It has increased from -3.60 (Mar 24) to 7.90, marking an increase of 11.50.
- For PBT Margin (%), as of Mar 25, the value is -0.53. This value is below the healthy minimum of 10. It has increased from -15.01 (Mar 24) to -0.53, marking an increase of 14.48.
- For Net Profit Margin (%), as of Mar 25, the value is -1.89. This value is below the healthy minimum of 5. It has increased from -16.86 (Mar 24) to -1.89, marking an increase of 14.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.56. This value is below the healthy minimum of 8. It has increased from -16.54 (Mar 24) to -1.56, marking an increase of 14.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.07. This value is below the healthy minimum of 15. It has increased from -13.78 (Mar 24) to -1.07, marking an increase of 12.71.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 3.90, marking an increase of 5.97.
- For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has increased from -6.05 (Mar 24) to -0.57, marking an increase of 5.48.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has increased from 0.26 (Mar 24) to 0.27, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has increased from 0.36 (Mar 24) to 0.38, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has increased from 0.78 (Mar 24) to 1.26, marking an increase of 0.48.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.55 (Mar 24) to 0.90, marking an increase of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.41. This value is within the healthy range. It has increased from 0.95 (Mar 24) to 4.41, marking an increase of 3.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 0.40 (Mar 24) to 1.79, marking an increase of 1.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 3. It has increased from -0.50 (Mar 24) to 0.77, marking an increase of 1.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25,036.75. It has increased from 10,872.67 (Mar 24) to 25,036.75, marking an increase of 14,164.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.31. This value exceeds the healthy maximum of 3. It has increased from 3.89 (Mar 24) to 8.31, marking an increase of 4.42.
- For EV / EBITDA (X), as of Mar 25, the value is 55.03. This value exceeds the healthy maximum of 15. It has decreased from 89.12 (Mar 24) to 55.03, marking a decrease of 34.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
- For Price / BV (X), as of Mar 25, the value is 5.30. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 5.30, marking an increase of 2.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.00, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Wockhardt Ltd:
- Net Profit Margin: -1.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.9% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.77
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 399 (Industry average Stock P/E: 47.84)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | D-4, MIDC, Aurangabad Maharashtra 431006 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Habil Khorakiwala | Founder Chairman |
| Dr. Murtaza Khorakiwala | Managing Director |
| Dr. Huzaifa Khorakiwala | Executive Director |
| Ms. Zahabiya Khorakiwala | Non Executive Director |
| Mrs. Tasneem Mehta | Independent Director |
| Mr. Vinesh Kumar Jairath | Independent Director |
| Mr. Akhilesh Gupta | Independent Director |
| Ms. Amelia Fernandes | Independent Director |
| Mr. Ahmad Javed | Independent Director |
FAQ
What is the intrinsic value of Wockhardt Ltd?
Wockhardt Ltd's intrinsic value (as of 22 January 2026) is ₹1955.84 which is 44.98% higher the current market price of ₹1,349.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹21,914 Cr. market cap, FY2025-2026 high/low of ₹1,870/1,110, reserves of ₹4,486 Cr, and liabilities of ₹8,533 Cr.
What is the Market Cap of Wockhardt Ltd?
The Market Cap of Wockhardt Ltd is 21,914 Cr..
What is the current Stock Price of Wockhardt Ltd as on 22 January 2026?
The current stock price of Wockhardt Ltd as on 22 January 2026 is ₹1,349.
What is the High / Low of Wockhardt Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Wockhardt Ltd stocks is ₹1,870/1,110.
What is the Stock P/E of Wockhardt Ltd?
The Stock P/E of Wockhardt Ltd is 399.
What is the Book Value of Wockhardt Ltd?
The Book Value of Wockhardt Ltd is 281.
What is the Dividend Yield of Wockhardt Ltd?
The Dividend Yield of Wockhardt Ltd is 0.00 %.
What is the ROCE of Wockhardt Ltd?
The ROCE of Wockhardt Ltd is 3.75 %.
What is the ROE of Wockhardt Ltd?
The ROE of Wockhardt Ltd is 1.22 %.
What is the Face Value of Wockhardt Ltd?
The Face Value of Wockhardt Ltd is 5.00.